The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer

Objective: Analyze the effect on survival of secondary cytoreduction surgery (SCS) in treatment of first recurrence platinum-sensitive epithelial ovarian cancer (REOC). Methods: Retrospective analysis of patients with first REOC who had platinum time-free interval (TFIp) > 6 months and were treated either with SCS followed by chemotherapy or chemotherapy only (CT). Clinical data such as patient’s performance status and number of sites with metastases were specifically assessed. The primary endpoint was overall survival (OS). Results: Seventy-one patients were treated either by SCS (n = 37) or CT (n = 34). Complete resection after SCS was achieved in 89% of patients. After a median follow-up of 51.2 months, median OS, and progression-free survival (PFS) were 68.2 and 21.6 months, respectively, for the whole series of the SCS patients had better survival and disease progression survival than the CT only patients (HR: 0.33, 95%CI: 0.17-0.6; p = 0.001) and (HR: 0.28, 95%CI: 0.15-0.5; p = 0.001), respectively. TFIp < 12 months and multiple metastases were most important prognostic factors for risk of death (HR: 7.7 and 6.2, respectively) and recurrence (HR: 5.8 and 3.8, respectively). Probability to undergo successful SCS is related to oligometastatic disease and no residual disease after first surgery (OR: 30.0 and 5.9, respectively). Conclusions: In women with REOC oligometastatic disease and no residual disease at first surgery are associated with successful SCS. In these patients oligometastatic disease and long platinum TFI are associated with improved probability of survival.

Ovarian cancer; Recurrence; Secondary cytoreductive surgery; Survival; Morbidity

[1] Pignata S., C Cecere S., Du Bois A., Harter P., Heitz F.: “Treatment of recurrent ovarian cancer”. Ann. Oncol., 2017, 28, viii51.

[2] Buechel M., Herzog T.J., Westin S.N., Coleman R.L., Monk B.J., Moore K.N.: “Treatment of patients with recurrent epithelial ovar­ ian cancer for whom platinum is still an option”. Ann. Oncol., 2019, 30, 721.

[3] Salani R., Santillan A., Zahurak M.L., Giuntoli R.L., Gardner G. J., Armstrong D. K., et al.: “Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer”. Cancer, 2007, 109, 685.

[4] Harter P., Bois A.D., Hahmann M., Hasenburg A., Burges A., Loibl S., et al.: “Surgery in Recurrent Ovarian Cancer: The Arbeitsge­ meinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial”. Ann. Surg. Oncol., 2006, 13, 1702.

[5] Eisenkop S.M., Friedman R.L., Spirtos N.M.: “The role of sec­ondary cytoreductive surgery in the treatment of patients with re­current epithelial ovarian carcinoma”. Cancer, 2000, 88, 144.

[6] Chi D.S., McCaughty K., Diaz J.P., Huh J., Schwabenbauer S., Hummer A.J., et al.: “Guidelines and selection criteria for sec­ondary cytoreductive surgery in patients with recurrent, platinum­ sensitive epithelial ovarian carcinoma”. Cancer, 2006, 106, 1933.

[7] Bristow R.E., Puri I., Chi D.S.: “Cytoreductive surgery for recurrent ovarian cancer: A meta­analysis”. Gynecol. Oncol., 2009, 112, 265.

[8] Laas E., Luyckx M., De Cuypere M., Selle F., Daraï E., Querleu D., et al.: “Secondary Complete Cytoreduction in Recurrent Ovarian Cancer: Benefit of Optimal Patient Selection Using Scoring Sys­ tem”. Int. J. Gynecol. Cancer., 2014, 24, 238.

[9] Muallem M.Z., Gasimli K., Richter R., Almuheimid J., Nasser S., Braicu E.I., Sehouli J.: “AGO Score As a Predictor of Surgical Out­ come at Secondary Cytoreduction in Patients with Ovarian Cancer”. Anticancer Res., 2015, 35, 3423.

[10] Zang R., Li Z., Tang J., Cheng X., Cai S., Zhang Z., et al.: “Sec­ondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: Who benefits?”. Cancer, 2004, 100, 1152.

[11] Salani R., Santillan A., Zahurak M.L., Giuntoli R.L., Gardner G.J., Armstrong D.K., et al.: “Secondary cytoreductive surgery for local­ ized, recurrent epithelial ovarian cancer”. Cancer, 2007, 109, 685.

[12] Zang R.Y., Harter P., Chi D.S., Sehouli J., Jiang R., Tropé C.G., et al.: “Predictors of survival in patients with recurrent ovarian can­ cer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort”. Br. J. Cancer, 2011, 105, 890­896.

[13] Tian W., Chi D.S., Sehouli J., Tropé C. G., Jiang R., Ayhan A., et al.: “A Risk Model for Secondary Cytoreductive Surgery in Re­current Ovarian Cancer: An Evidence­Based Proposal for Patient Selection”. Ann. Surg. Oncol., 2012, 19, 597.

[14] van de Laar R., Massuger L.F.A.G., Van Gorp T., IntHout J., Zusterzeel P.L.M., Kruitwagen R.F.P.M.: “External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer”. Gynecol. On­ col., 2015, 137, 210.

[15] Oksefjell H., Sandstad B., Tropé C.: “The role of secondary cytore­ duction in the management of the first relapse in epithelial ovarian cancer”. Ann. Oncol., 2009, 20, 286.

[16] Felsinger M., Minar L., Weinberger V., Rovny I., Zlamal F., Bienertova­Vasku J.: “Secondary cytoreductive surgery ­ viable treatment option in the management of platinum­sensitive recurrent ovarian cancer”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2018, 228, 154.

[17] Szczesny W., Cancer Registry of Norway; Institute of Population­ based Cancer Research; Oslo Norway, Langseth H., Myklebust T.,̇ Department of Research; Møre and Romsdal Hospital Trust; Åle­ sund Norway, Kaern J., et al.: “Survival after secondary cytore­ ductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum­sensitive ep­ ithelial ovarian cancer and no residuals after primary treatment. A registry­based study”. Acta Obstet. Gynecol. Scand., 2018, 97, 956.

[18] Gockley A., Melamed A., Cronin A., Bookman M.A., Burger R.A., Cristae M.C., et al.: “Outcomes of secondary cytoreductive surgery for patients with platinum­sensitive recurrent ovarian cancer”. am. J. Obstet. Gynecol., 2019, 221, 625.e1.

[19] Du Bois A., Sehouli J., Vergote I., Ferron G., Reuss A., Meier W., et al.: “Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Fi­ nal analysis of AGO DESKTOP IIIENGOT­ov20.”. J. Clin. Oncol., 2020, 38, 6000.

[20] Coleman R.L., Brady M.F., Herzog T.J., Sabbatini P., Armstrong D.K., Walker J.L., et al.: “Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum­ sensitive ovarian cancer (NRG OncologyGynecologic Oncology Group study GOG­0213): a multicentre, open­label, randomised, phase 3 trial”. Lancet Oncol., 2017, 18, 779.

[21] Coleman R.L., Spirtos N.M., Enserro D., Herzog T.J., Sabbatini P., Armstrong D.K., et al.: “Secondary Surgical Cytoreduction for Re­ current Ovarian Cancer”. N. Engl. J. Med., 2019, 381, 1929.

[22] Dindo D., Demartines N., Clavien P.: “Classification of Surgical Complications”. Ann. Surg., 2004, 240, 205.

[23] Zang R., Li Z., Tang J., Cheng X., Cai S., Zhang Z., et al.: “Sec­ ondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: Who benefits?”. Cancer, 2004, 100, 1152.

[24] Petrillo M., Fagotti A., Ferrandina G., Fanfani F., Costantini B., Vizzielli G., et al.: “Ovarian cancer patients with localized relapse: Clinical outcome and prognostic factors”. Gynecol. Oncol., 2013, 131, 36.

[25] Colombo N., Sessa C., Bois A.D., Ledermann J., McCluggage W., McNeish I., et al.: “ESMO–ESGO consensus conference recom­ mendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent dis­ ease”. Ann Oncol., 2019, 30, 672.

[26] Aghajanian C., Goff B., Nycum L.R., Wang Y.V., Husain A., Blank S.V.: “Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in pa­ tients with platinum­sensitive recurrent ovarian cancer”. Gynecol. Oncol., 2015, 139, 10.

[27] Feldheiser A., Yosef A.B., Braicu E.I., Bonomo T., Kaufner L., Spies C., et al. Surgery at primary versus relapsed epithelial ovarian cancer: a study on aspects of anesthesiologic management. Anti­ cancer. Res., 2015; 35, 1591e1601.